ReviewSeminars in immunopathology2023

Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.

Francesco De Sanctis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.